Corvus Pharmaceuticals (CRVS) PT Lowered to $8 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CRVS Hot Sheet
Price: $10.53 -1.13%
Rating Summary:
14 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
14 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Wedbush analyst Robert Driscoll lowered the price target on Corvus Pharmaceuticals (NASDAQ: CRVS) to $8.00 (from $11.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Tango Therapeutics Inc. (TNGX) PT Raised to $45 at Wedbush
- FirstService Corp (FSV) PT Lowered to $179 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
